Immunomedics, Inc., a biopharmaceutical company, develops monoclonal antibody-based products for the treatment of cancer, autoimmune, and other serious diseases. Its lead product candidate is epratuzumab, which is in two pivotal Phase III trials for the treatment of patients with moderate and severe lupus. The company's other products include IMMU-106, which is in Phase I/II clinical trials in patients with B-cell non-Hodgkin's lymphoma; and PAM4, a humanized monoclonal antibody for the treatment of pancreatic cancer. It also markets and sells LeukoScan, a diagnostic product used for the detection of bone infections, in Europe, Canada, and the United States. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.